Spark Therapeutics (ONCE) Receiving Somewhat Positive News Coverage, Report Finds

Media headlines about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.8481587962074 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Spark Therapeutics (NASDAQ ONCE) opened at $63.09 on Monday. The company has a market capitalization of $2,348.02, a PE ratio of -8.16 and a beta of 2.82. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) EPS for the quarter, meeting the consensus estimate of ($1.73). The firm had revenue of $7.41 million during the quarter, compared to the consensus estimate of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. equities analysts expect that Spark Therapeutics will post -3.42 EPS for the current fiscal year.

Several research firms recently weighed in on ONCE. Raymond James Financial reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Spark Therapeutics in a research note on Thursday, December 7th. BMO Capital Markets set a $73.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Tuesday, December 12th. Barclays reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Finally, ValuEngine lowered Spark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company. Spark Therapeutics has a consensus rating of “Buy” and a consensus target price of $70.58.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics (ONCE) Receiving Somewhat Positive News Coverage, Report Finds” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3300979/spark-therapeutics-once-receiving-somewhat-positive-news-coverage-report-finds.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ONEOK  Receives Daily News Sentiment Rating of 0.13
ONEOK Receives Daily News Sentiment Rating of 0.13
AvalonBay Communities  Receives Coverage Optimism Score of 0.14
AvalonBay Communities Receives Coverage Optimism Score of 0.14
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Corning  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Corning Stock Price
Global Tour Coin  Market Cap Reaches $203,029.00
Global Tour Coin Market Cap Reaches $203,029.00
MktCoin  Reaches One Day Trading Volume of $32,488.00
MktCoin Reaches One Day Trading Volume of $32,488.00
Dreamcoin Price Reaches $0.0166 on Major Exchanges
Dreamcoin Price Reaches $0.0166 on Major Exchanges


© 2006-2018 Ticker Report. Google+.